HIV-1 PASSIVE IMMUNITY AGAINST CORECEPTOR INTERACTIONS
HIV-1 针对辅助受体相互作用的被动免疫
基本信息
- 批准号:6147522
- 负责人:
- 金额:$ 2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-02-07 至 2002-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION
(Adapted from the applicant's abstract) The molecules involved in HIV-1
entry have now been identified making it possible to target this process for
strategies to inhibit viral infection. The process requires two molecular
entities, a coreceptor that also binds chemokines and a complex formed
between the HIV-1 envelope, gp120, and the primary cell receptor, CD4.
Antibodies that bind to epitopes involved in the coreceptor interaction
should neutralize HIV-1 and therefore be useful for passive immunity to
prevent or treat infection. In this project, the investigators will use two
strategies to raise such antibodies in mice. The first will be immunization
with covalently crosslinked gp120-CD4 complexes to raise monoclonal
antibodies against the coreceptor binding site on the viral envelope. The
investigators have already shown that these complexes elicit broadly
neutralizing responses that interfere in a post-CD4 binding step. The
second will be to raise antibodies specific for the viral attachment site on
the coreceptors CCR5 and CxCR4. Neutralizing mAbs that block entry
processes will be "humanized" by recombinant DNA methods developed by this
group to provide reagents for passive immunotherapy. This approach, which
allows the investigators to manipulate specific immunogens in order to
obtain the desired responses, will allow them to isolate neutralizing mAbs
from mice and to characterize them in less time than it would take to
identify, characterize, and isolate the human counterparts.
描述
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anthony L DeVico其他文献
Anthony L DeVico的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anthony L DeVico', 18)}}的其他基金
CCR5 determinants for the HIV transmitted founder phenotype
HIV 传播创始人表型的 CCR5 决定因素
- 批准号:
10760884 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
Detection Assays for Virion Susceptibility to HIV Broadly Neutralizing Antibodies in Plasma and Culture Fluids
血浆和培养液中病毒体对 HIV 广泛中和抗体敏感性的检测分析
- 批准号:
10675310 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
Novel bNAB-based treatment and prevention of HIV-1
基于 bNAB 的 HIV-1 新型治疗和预防
- 批准号:
10653146 - 财政年份:2021
- 资助金额:
$ 2万 - 项目类别:
Novel bNAB-based treatment and prevention of HIV-1
基于 bNAB 的 HIV-1 新型治疗和预防
- 批准号:
10445321 - 财政年份:2021
- 资助金额:
$ 2万 - 项目类别:
Novel bNAB-based treatment and prevention of HIV-1
基于 bNAB 的 HIV-1 新型治疗和预防
- 批准号:
10324861 - 财政年份:2021
- 资助金额:
$ 2万 - 项目类别:
Project 1-Mechanism of Anti-Gp120 Antibody Persistence
项目1-抗Gp120抗体持久性机制
- 批准号:
9141192 - 财政年份:2016
- 资助金额:
$ 2万 - 项目类别:
Single Chain Complex Vaccines and Protective Immunity
单链复合疫苗和保护性免疫
- 批准号:
7515045 - 财政年份:2005
- 资助金额:
$ 2万 - 项目类别:
HIV Vaccines Based on GP120-CD4 Mimetic Complexes
基于 GP120-CD4 模拟复合物的 HIV 疫苗
- 批准号:
7121362 - 财政年份:2005
- 资助金额:
$ 2万 - 项目类别:
HIV Vaccines Based on GP120-CD4 Mimetic Complexes
基于 GP120-CD4 模拟复合物的 HIV 疫苗
- 批准号:
7039242 - 财政年份:2005
- 资助金额:
$ 2万 - 项目类别:
HIV Vaccines Based on GP120-CD4 Mimetic Complexes
基于 GP120-CD4 模拟复合物的 HIV 疫苗
- 批准号:
7510135 - 财政年份:2005
- 资助金额:
$ 2万 - 项目类别: